Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.61 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466963 | 0.86 | AR (0.49) | ARFNTAFNTBPGGT1BTSHR | |
| SCHEMBL6464447 | 0.83 | AR (0.53) | ARFNTAFNTBTSHRMEN1 | |
| SCHEMBL6466939 | 0.83 | AR (0.67) | ARTSHRMEN1KMT2APTGDR2 | |
| SCHEMBL6466315 | 0.80 | AR (0.59) | ARTSHRMEN1KMT2APTGDR2 | |
| SCHEMBL6466727 | 0.78 | AR (0.60) | ARMEN1KMT2APTGDR2MAPT | |
| SCHEMBL6469613 | 0.78 | AR (0.57) | ARTSHRMEN1KMT2APTGDR2 | |
| SCHEMBL6466328 | 0.78 | AR (0.57) | ARTSHRMEN1KMT2APTGDR2 | |
| SCHEMBL6468911 | 0.76 | AR (1.00) | ARTSHRTDP1MAPTLMNA | |
| SCHEMBL6889627 | 0.75 | AR (0.67) | ARPTGDR2KDM4ELMNA | |
| SCHEMBL13356428 | 0.75 | AR (0.56) | ARTSHRTDP1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885FNTA 3791/4885FNTB 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.